CCAR-066 is under clinical development by Janssen Biotech and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CCAR-066’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CCAR-066 overview

CCAR-066 (CBM.CD20 CAR-T) is under development for the treatment of chemotherapy resistant or refractory CD20+ leukemia and lymphoma including b-cell non-Hodgkin lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone b-cell lymphoma, B-cell prolymphocytic leukemia (PLL) and diffuse large B-cell lymphoma. The therapy is administered through intravenous route as infusion. The therapy is composed of anti-CD20-CAR lentivirus vector-transduced autologous T cells that target CD20 cancer cells.

It was also under development for the treatment of refractory chronic lymphocytic leukemia (CLL).

Janssen Biotech overview

Janssen Biotech, a subsidiary of Johnson & Johnson, is a manufacturer and markets solutions for oncology, immunology, cardiovascular, and metabolic diseases that develop and commercializes therapeutic and diagnostic products. The company is headquartered in Montgomery, Pennsylvania, the US.

For a complete picture of CCAR-066’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.